Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire•25/09/2026•16:15 ET
0
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
SAN FRANCISCO, Sept. 25, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on September 18, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 58,600 shares of its common stock and 2,450 restricted stock units (RSUs) to eleven newly-hired employees under Nektar's 2025 Inducement Plan.
Get started
Create a free account to read the full story and Whiz Insights.